This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

The future of care for people with severe asthma


St Pancras, London

A national workshop for respiratory leaders across primary, secondary, tertiary care and commissioning. It will focus on improvements in uncontrolled and severe asthma pathways and share learning from the two-year asthma biologics programme led by the Oxford AHSN on behalf of the AHSN Network in partnership with the NHS Accelerated Access Collaborative (AAC).

Hosted by the Oxford AHSN, this workshop will be chaired by Dr Hitasha Rupani, clinical champion for the asthma biologics programme and consultant respiratory physician at University Hospital Southampton NHS Foundation Trust. Twenty six speakers are confirmed. They include from NHS England:

  • Jonathan Fuld, National Clinical Director
  • Kathy Blacker who will present about the future for commissioning specialised severe asthma services

The sessions will hear first-hand from all nine successful Pathway Transformation Fund projects from around the country on how they have delivered pathway change, built effective new networks and supported earlier identification to improve access to severe asthma care and biologic therapies for patients with severe and uncontrolled asthma.

Up to 200,000 people in the UK have uncontrolled or severe asthma, which has a huge impact on the lives of patients and their families. Many are frequently admitted to hospital as an emergency and can experience life-threatening asthma attacks.

Asthma biologics work in a targeted way by disrupting pathways causing airways inflammation, helping to manage symptoms and reduce relapses for those with severe asthma. These therapies can transform patients’ lives by reducing long-term side effects of other treatments, such as steroids, and reduce the number of life-threatening asthma attacks.

From April 2021 to March 2023 AHSNs in England, led by the Oxford AHSN, supported the adoption and spread of asthma biologics, under the AAC Rapid Uptake Products programme. More than 4,690 new patients have been initiated onto asthma biologics and around 3,000 fewer patients were prescribed 3g or more of oral steroid prednisolone each month.


Event Types: Clinical Innovation Adoption AHSN Network